Recent developments in therapeutics for prion diseases

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 1, 2008, Pages 35-59

  Sakaguchi, Suehiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Prion; Prion disease; Prion protein; Therapeutics

Indexed keywords

AMPHOTERICIN B; ANTIMONIOTUNGSTATE; BENZOXAZOLE DERIVATIVE; BF 168; CARRAGEENAN; CHLORPROMAZINE; CONGO RED; DEXTRAN SULFATE; DOXORUBICIN DERIVATIVE; DOXYCYCLINE; EVANS BLUE; FLUPIRTINE; HEPARAN SULFATE; IMATINIB; MEPACRINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PENTOSAN POLYSULFATE; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOROTHIOIC ACID; PHTHALOCYANINE DERIVATIVE; POLYAMIDOAMINE; POLYETHYLENEIMINE; PORPHYRIN DERIVATIVE; PRION PROTEIN; SIMVASTATIN; SPERMINE DERIVATIVE; SURAMIN; TETRACYCLINE; TRYPAN BLUE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; BIBLIOGRAPHIC DATABASE; BLOOD BRAIN BARRIER; BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN HEMORRHAGE; CARCINOGENICITY; CATTLE DISEASE; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; HAMSTER; HUMAN; INCUBATION TIME; INTERNET; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NONHUMAN; PATENT; PATHOGENESIS; PATHOGENICITY; PIGMENT DISORDER; PRION; PRION DISEASE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; SUBDURAL EFFUSION; SURVIVAL RATE; UNITED KINGDOM;

EID: 39749110601     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.1.35     Document Type: Review

References (199)

1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95(23):13363-83
2. Dearmond SJ, Prusiner SB. Etiology and pathogenesis of prion diseases. Am J Pathol 1995;146(4):785-811
3. Duffy P, Wolf J, Collins G, et al. Possible person-to-person transmission of Creutzfeldt-Jakob disease [letter]. N Engl J Med 1974;290(12):692-3
4. Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1977;1(8009):478-9
5. Koch TK, Berg BO, De Armond SJ, Gravina RF. Creutzfeldt-Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation to the administration of cadaveric human growth hormone. N Engl J Med 1985;313(12):731-3
6. Thadani V, Penar PL, Parrington J, et al. Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. Case report. J Neurosurg 1988;69(5):766-9
7. Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977;197(4307):943-60
8. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997;389(6650):498-501
9. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997;389(6650):448-50, 526
10. Collee JG, Bradley R, Liberski PP. Variant CJD (vCJD) and bovine spongiform encephalopathy (BSE): 10 and 20 years on: part 2. Folia Neuropathol 2006;44(2):102-10
11. Peden AH, Ritchie DL, Ironside JW. Risks of transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Folia Neuropathol 2005;43(4):271-8
12. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363(9407):417-21
13. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364(9433):527-9
14. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006;129(Pt 9):2241-65
15. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62(5):714-8
16. Benito-Leon J. Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 2004;27(4):201-3
17. Nakajima M, Yamada T, Kusuhara T, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Demerit Geriatr Cogn Disord 2004;17(3):158-63
18. Todd NV, Morrow J, Doh-Ura K, et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 2005;50(5):394-6
19. Rainov NG, Tsuboi Y, Krolak-Salmon P. Vighetto A, Doh-Ura K. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin Biol Ther 2007;7(5):713-26
20. Prusiner SB. Prions: novel infectious pathogens. Adv Virus Res 1984;29:1-56
21. Weissmann C, Enari M, Klohn PC, Rossi D, Flechsig E. Molecular biology of prions. Acta Neurobiol Exp (Wars) 2002;62(3):153-66
22. Legname G, Baskakov IV, Nguyen HO, et al. Synthetic mammalian prions. Science 2004;305(5684):673-6
23. Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature 2005;437(7056):257-61
24. Hundt C, Peyrin JM, Haik S, et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J 2001;20(21):5876-86
25. Gauczynski S, Nildes D, El-Gogo S, et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis 2006;194(5):702-9
26. Vana K, Weiss S. A trans-dominant negative 37kDa/67kDa laminin receptor mutant impairs PrP(Sc) propagation in scrapie-infected neuronal cells. J Mol Biol 2006;358(1):57-66
27. Leucht C, Simoneau S, Rey C, et al. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep 2003;4(3):290-5
28. Harris DA. Cellular biology of prion diseases. Clin Microbiol Rev 1999;12(3):429-44
29. Gorodinsky A, Harris DA. Glycolipid-anchored proteins in neuroblascoma cells form detergent-resistant complexes without caveolin. J Cell Biol 1995;129(3):619-27
30. Taraboulos A, Scott M, Semenov A, et al. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 1995;129(1):121-32
31. Vey M, Pilkuhn S, Wille H, et al. Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci USA 1996;93(25):14945-9
32. Sarnataro D, Campana V, Paladino S, et al. PrP(C) association with lipid rafts in the early secretary pathway stabilizes its cellular conformation. Mol Biol Cell 2004;15(9):4031-42
33. Bate C, Salmona M, Diomede L, Williams A. Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem 2004;279(15):14983-90
34. Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000;74(10):4894-7
35. Kocisko DA, Come JH, Priola SA, et al. Cell-free formation of protease-resistant prion protein. Nature 1994;370(6489):471-4
36. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001;411(6839):810-3
37. Castilla J, Saa P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. Cell 2005;121(2):195-206
38. Race RE, Fadness LH, Chesebro B. Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol 1987;68(Pt 5):1391-9
39. Nishida N, Harris DA, Vilette D, et al. Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J Virol 2000;74(1):320-5
40. Schatzl HM, Laszlo L, Holtzman DM, et al. A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J Virol 1997;71(11):8821-31
41. MRC Clinical Trials Unit. PRION-1: Randomised trial of quinacrine in human prion disease. Available at: URL:www.ctu.mrc.ac.uk/studies/cjd.asp [Accessed January 2008]
42. Kimberlin RH, Walker CA. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol 1983;78(1-2):9-18
43. Dealler Stephen Francis (GB). GB2334211 (1999)
44. Sangaku Renkei Kiko Kyushu KK. JP2003040778; 2003
45. Gabizon R, Meiner Z, Halimi M, Ben-Sasson SA. Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic fate. J Cell Physiol 1993;157(2):319-25
46. Caughey B, Raymond GJ. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 1993;67(2):643-50
47. Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected]. J Virol 1994;68(4):2135-41
48. Adjou KT, Simoneau S, Sales N, et al. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J Gen Virol 2003;84(Pt 9):2595-603
49. Schonberger O, Horonchik L, Gabizon R, et al. Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. Biochem Biophys Res Commun 2003;312(2):473-9
50. Replicor, Inc. (CA). CA2538245 (2005)
51. Replicor, Inc. (CA); Juteau Jean-MARC (CA); Vaillant Andrew (CA). WO2006002540 (2006)
52. Replicor, Inc. (CA). US2007123480 (2007)
53. Kocisko DA, Vaillant A, Lee KS, et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob Agents Chemother 2006;50(3):1034-44
54. Karpuj MV, Giles K, Gelibter-Niv S, et al. Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells. Mol Med (Cambridge, Mass) 2007;13(3-4):190-8
55. Nat Inst of Asv Ind & Technol; Nat Veterinary Assay Lab Minis; Nat Agriculture & Food Res Org. JP2006320289 (2006)
56. Proske D, Gilch S, Wopfner F, et al. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 2002;3(8):717-25
57. Rhie A, Kirby L, Sayer N, et al. Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem 2003;278(41):39697-705
58. Shyng SL, Lehmann S, Moulder KL, Harris DA. Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J Biol Chem 1995;270(50):30221-9
59. Kimberlin RH, Walker CA. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother 1986;30(3):409-13
60. Ehlers B, Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 1984;65(Pt 8):1325-30
61. Farquhar CF, Dickinson AG. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 1986;67(Pt 3):463-73
62. Ladogana A, Casaccia P, Ingrosso L, et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992;73(Pt 3):661-5
63. Doh-Ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004;78(10):4999-5006
64. Supattapone S, Wille H, Uyechi L, et al. Branched polyamines cure prion-infected neuroblastoma cells. J Virol 2001;75(7):3453-61
65. Solassol J, Crozet C, Perrier V, et al. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol 2004;85(Pt 6):1791-9
66. Winklhofer KF, Tatzelt J. Cationic lipopolyamines induce degradation of PrPSc in scrapie-infected mouse neuroblastoma cells. Biol Chem 2000;381(5-6):463-9
67. Yudovin-Farber I, Azzam T, Metzer E, Taraboulos A, Domb AJ. Cationic polysaccharides as antiprion agents J Med Chem 2005;48(5):1414-20
68. Supattapone S, Nguyen HO, Cohen FE, Prusiner SB, Scott MR. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci USA 1999;96(25):14529-34
69. US Health (US). WO9401116 (1994)
70. Caughey B, Race RE. Potent inhibition of scrapie-associated PrP accumulation by congo red. J Neurochem 1992;59(2):768-71
71. Demaimay R, Chesebro B, Caughey B. Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red and other Congo Red analogs. Arch Virol Suppl 2000;(16):277-83
72. Ingrosso L, Ladogana A, Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol 1995;69(1):506-8
73. Poli G, Martino PA, Villa S, et al. Evaluation of antiprion activity of congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung 2004;54(7):406-15
74. Gray LE Jr, Ostby JS. The effects of prenatal administration of azo dyes on testicular development in the mouse: a structure activity profile of dyes derived from benzidine, dimethylbenzidine, or dimethoxybenzidine. Fundam Appl Toxicol 1993;20(2):177-83
75. Rudyk H, Vasiljevic S, Hennion RM, et al. Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J Gen Virol 2000;81(Pt 4):1155-64
76. Rudyk H, Knaggs MH, Vasiljevic S, et al. Synthesis and evaluation of analogues of Congo red as potential compounds against transmissible spongiform encephalopathies. Eur J Med Chem 2003;38(6):567-79
77. Demaimay R, Harper J, Gordon H, et al. Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J Neurochem 1998;71(6):2534-41
78. Caspi S, Halimi M, Yanai A, et al. The antiprion activity of Congo red. Putative mechanism. J Biol Chem 1998;273(6):3484-9
79. Ishikawa K, Kudo Y, Nishida N, et al. Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies. J Neurochem 2006;99(1):198-205
80. Kawasaki Y, Kawagoe K, Chen CJ, et al. Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol 2007;81(23):12889-98
81. Barbieri B, Giuliani FC, Bordoni T, et al. Chemical and biological characterization of 4′-iodo-4′-deoxydoxorubicin. Cancer Res 1987;47(15):4001-6
82. Tagliavini F, McArthur RA, Canciani B, et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997;276(5315):1119-22
83. Forloni G, Iussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 2002;99(16):10849-54
84. Tagliavini F, Forloni G, Colombo L, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000;300(5):1309-22
85. Gilch S, Winklhofer KF, Groschup MH, et al. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J 2001;20(15):3957-66
86. Nunziante M, Kehler C, Maas E, et al. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. J Cell Sci 2005;118(Pt 21):4959-73
87. Priola SA, Caughey B, Caughey WS. Novel therapeutic uses for porphyrins and phthalocyanines in the transmissible spongiform encephalopathies. Curr Opin Microbiol 1999;2(5):563-6
88. Caughey WS, Raymond LD, Horiuchi M, Caughey B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci USA 1998;95(21):12117-22
89. US Health (US); Caughey Winslow S (US); Caughey Byron (US). WO0009111 (2000)
90. US Health (US). US6632808 (2003)
91. Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000;287(5457):1503-6
92. Priola SA, Raines A, Caughey W. Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. J Infect Dis 2003;188(5):699-705
93. Kocisko DA, Caughey WS, Race RE, et al. A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob Agents Chemother 2006;50(2):759-61
94. Caughey WS, Priola SA, Kocisko DA, et al. Cyclic tetrapyrrole sulfonation, metals, and oligomerization in antiprion activity. Antimicrob Agents Chemother 2007;51(11):3887-94
95. Adjou KT, Demaimay R, Deslys JP, et al. MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. J Gen Virol 1999;80(Pt 4):1079-85
96. Demaimay R, Race R, Chesebro B. Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons. J Virol 1999;73(4):3511-3
97. Amyx H, Salazar DC, Gajdusek DC, Gibbs CJ Jr. Chemotherapeutic trials in experimental slow virus diseases. Neurology 1984;34(Suppl 1):149
98. Demaimay R, Adjou KT, Beringue V, et al. Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J Virol 1997;71(12):9685-9
99. Mange A, Nishida N, Milhavet O, et al. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J Virol 2000;74(7):3135-40
100. Brajtburg J, Elberg S, Bolard J, et al. Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis 1984;149(6):986-97
101. Caughey B, Baron GS. Prions and their partners in crime. Nature 2006;443(7113):803-10
102. Saint-Julien L, Joly V, Seman M, Carbon C, Yeni P. Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses. Antimicrob Agents Chemother 1992;36(12):2722-8
103. Adjou KT, Demaimay R, Lasmezas C, et al. MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob Agents Chemother 1995;39(12):2810-2
104. Pocchiari M, Casaccia P, Ladogana A. Amphotericin B: a novel class of antiscrapie drugs. J Infect Dis 1989;160(5):795-802
105. Marella M, Lehmann S, Grassi J, Chabry J. Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J Biol Chem 2002;277(28):25457-64
106. Sviridov D, Nestel P, Watts G. Statins and metabolism of high density lipoprotein. Cardiovasc Hematol Agents Med Chem 2007;5(3):215-21
107. Glassberg H, Rader DJ. Management of lipids in the prevention of cardiovascular events. Ann Rev Med 2007; In Press
108. Mok SW, Thelen KM, Riemer C, et al. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem Biophys Res Commun 2006;348(2):697-702
109. Kempster S, Bate C, Williams A. Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport 2007;18(5):479-82
110. Univ California (US); Prusiner Stanley B (US); Korth Carsten (US); May Barnaby CH (US). WO02096431 (2002)
111. Touchsensor Tech LLC (US). US2005020582 (2005)
112. Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003;77(15):8462-9
113. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98(17):9836-41
114. Roikhel VM, Fokina GI, Pogodina VV. Influence of aminasine on experimental scrapie in mice. Acta Virol 1984;28(4):321-4
115. Univ California (US). US2004229898 (2004)
116. Univ California (US); Prusiner Stanley B (US); Korth Carsten (US); May Barnaby CH (US). WO2005027824 (2005)
117. May BC, Fafarman AT, Hong SB, et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci USA 2003;100(6):3416-21
118. Sangaku Renkei Kiko Kyushu KK. JP2004099553 (2004)
119. Murakami-Kubo I, Doh-Ura K, Ishikawa K, et al. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol 2004;78(3):1281-8
120. Kocisko DA, Caughey B. Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo. J Virol 2006;80(2):1044-6
121. Ertmer A, Gilch S, Yun SW, et al. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem 2004;279(40):41918-27
122. Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J 2007;13(6):357-65
123. Petzer AL, Gunsilius E, Hayes M, et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. B J Haematol 2002;117(3):623-5
124. Yun SW, Ertmer A, Flechsig E, et al. The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. J Neurovirol 2007;13(4):328-37
125. Bate C, Reid S, Williams A. Phospholipase A2 inhibitors or platetet-activating factor antagonists prevent prion replication. J Biol Chem 2004;279(35):36405-11
126. Farooqui AA, Ong WY, Horrocks LA. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 2006;58(3):591-620
127. Nordstrom EK, Luhr KM, Ibanez C, Kristensson K. Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc. J Neurosci 2005;25(37):8451-6
128. Bueler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993;73(7):1339-47
129. Prusiner SB, Groth D, Serban A, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci USA 1993;90(22):10608-12
130. Sakaguchi S, Katamine S, Shigematsu K, et al. Accumulation of proteinase K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent. J Virol 1995;69(12):7586-92
131. Manson JC, Clarke AR, McBride PA, McConnell I, Hope J. PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration 1994;3(4):331-40
132. Mallucci GR, White MD, Farmer M, et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 2007;53(3):325-35
133. Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003;302(5646):871-4
134. Alnylam Europ AG (DE). EP1550719 (2005)
135. Alnylam Europ AG (DE). JP2007031443 (2007)
136. Alnylam Europ AG (DE). EP1798285 (2007)
137. Japan Health Sciences Foundation (JP); Hohjoh Hirohiko (JP). WO2005078093 (2005)
138. Tilly G, Chapuis J, Vilette D, Laude H, Vilotte JL. Efficient and specific down-regulation of prion protein expression by RNAi. Biochem Biophys Res Commun 2003;305(3):548-51
139. Daude N, Marella M, Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 2003;116(Pt 13):2775-9
140. Pfeifer A, Eigenbrod S, Al-Khadra S, et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 2006;116(12):3204-10
141. Collinge J, Whittington MA, Sidle KC, et al. Prion protein is necessary for normal synaptic function. Nature 1994;370(6487):295-7
142. Tobler I, Gaus SE, Deboer T, et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 1996;380(6575):639-42
143. Nishida N, Tremblay P, Sugimoto T, et al. A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. Lab Invest 1999;79(6):689-97
144. McLennan NF, Brennan PM, McNeill A, et al. Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol 2004;165(1):227-35
145. Sakurai-Yamashita Y, Sakaguchi S, Yoshikawa D, et al. Female-specific neuroprotection against transient brain ischemia observed in mice devoid of prion protein is abolished by ectopic expression of prion protein-like protein. Neuroscience 2005;136(1):281-7
146. Gauczynski S, Peyrin JM, Haik S, et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001;20(21):5863-75
147. Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 2001;98(16):9295-9
148. Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001;412(6848):739-43
149. Donofrio G, Heppner FL, Polymenidou M, Musahl C, Aguzzi A. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 2005;79(13):8330-8
150. Polymenidou M, Heppner FL, Pellicioli EC, et al. Humoral immune response to native eukaryotic prion protein correlates with antiprion protection. Proc Natl Acad Sci USA 2004;101(Suppl 2):14670-6
151. Korth C, Stierli B, Streit P, et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 1997;390(6655):74-7
152. Medical Res Council (GB). US2006280745 (2006)
153. White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003;422(6927):80-3
154. Perrier V, Solassol J, Crozet C, et al. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem 2004;89(2):454-63
155. Miyamoto K, Nakamura N, Aosasa M, et al. Inhibition of prion propagation in scrapie-infected mouse neuroblastoma cell lines using mouse monoclonal antibodies against prion protein. Biochem Biophys Res Commun 2005;335(1):197-204
156. Kim CL, Karino A, Ishiguro N, et al. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J Gen Virol 2004;85(Pt 11):3473-82
157. Stefan Weiss (DE/DE); Melvyn Little (GB/DE); Stefan Knackmuss (DE/DE); Clemence Rey (FR/DE); Peter Rottgen (DE/DE); Claudia Buttner (DE/DE); UWE Reusch (DE/DE). WO2005/035580 (2005)
158. Zuber C, Knackmuss S, Rey C, et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2008;45(1):144-51
159. Meier P, Genoud N, Prinz M, et al. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell 2003;113(1):49-60
160. Univ Zuerich (CH). CA2518549 (2004)
161. Univ Zuerich (CH). EP1603951 (2005)
162. Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/ lymphoma. Oncogene 2007;26(25):3699-703
163. Stinchcombe TE, Socinski MA. Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 2007;26(25):3691-8
164. Kavanaugh A. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment-data from randomized clinical trials. Bull NYU Hosp Joint Dis 2007;65(Suppl 1):S16-20
165. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6(5 Pt 1):859-66
166. Ludewigs H, Zuber C, Vana K, et al. Therapeutic approaches for prion disorders. Expert Rev Antiinfect Ther 2007;5(4):613-30
167. Sigurdsson EM, Brown DR, Daniels M, et al. Immunization delays the onset of prion disease in mice. Am J Pathol 2002;161(1):13-7
168. Ishibashi D, Yamanaka H, Yamaguchi N, et al. Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion. Vaccine 2007;25(6):985-92
169. Goni F, Knudsen E, Schreiber F, et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 2005;133(2):413-21
170. Szelenyi I, Nickel B, Borbe HO, Brune K. Mode of antinociceptive action of flupirtine in the rat. B J Pharmacol 1989;97(3):835-42
171. Dhar S, Bitting RL, Rylova SN, et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol 2002;51(4):448-66
172. Perovic S, Schroder HC, Pergande G, Ushijima H, Muller WE. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 1997;147(2):518-24
173. Forloni G, Angeretti N, Chiesa R, et al. Neurotoxicity of a prion protein fragment. Nature 1993;362(6420):543-6
174. Wong BS, Brown DR, Pan T, et al. Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. J Neurochem 2001;79(3):689-98
175. Choi SI, Ju WK, Choi EK, et al. Mitochondrial dysfunction induced by oxidative stress in the brains of hamsters infected with the 263 K scrapie agent. Acta Neuropathol (Berl) 1998;96(3):279-86
176. Milhavet O, McMahon HE, Rachidi W, et al. Prion infection impairs the cellular response to oxidative stress. Proc Natl Acad Sci USA 2000;97(25):13937-42
177. Guentchev M, Voigtlander T, Haberler C, Groschup MH, Budka H. Evidence for oxidative stress in experimental prion disease. Neurobiol Dis 2000;7(4):270-3
178. Guentchev M, Siedlak SL, Jarius C, et al. Oxidative damage to nucleic acids in human prion disease. Neurobiol Dis 2002;9(3):275-81
179. Drisko JA. The use of antioxidants in transmissible spongiform encephalopathies: a case report. J Am Coll Nutr 2002;21(1):22-5
180. Castilla J, Hetz C, Soto C. Molecular mechanisms of neurotoxicity of pathological prion protein. Curr Mol Med 2004;4(4):397-403
181. Hetz C, Russelakis-Carneiro M, Maundrell K, Castilla J, Soto C. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J 2003;22(20):5435-45
182. Lindholm D, Wootz H, Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ 2006;13(3):385-92
183. Paschen W. Endoplasmic reticulum: a primary target in various acute disorders and degenerative diseases of the brain. Cell Calcium 2003;34(4-5):365-83
184. Zhao L, Ackerman SL. Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol 2006;18(4):444-52
185. Kocisko DA, Baron GS, Rubenstein R, et al. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 2003;77(19):10288-94
186. Kocisko DA, Morrey JD, Race RE, Chen J, Caughey B. Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice. J Gen Virol 2004;85(Pt 8):2479-83
187. Maxson L, Wong C, Herrmann LM, Caughey B, Baron GS. A solid-phase assay for identification of modulators of prion protein interactions. Anal Biochem 2003;323(1):54-64
188. Bach S, Talarek N, Andrieu T, et al. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 2003;21(9):1075-81
189. Ludwig Maximilians Uni Muenche (DE); Max Planck Gesellschaft (DE); Bertsch UWE (DE); Giese Armin (DE); Kretzschmar Hans (DE); Tavan Paul (DE); Hirschberger Thomas (DE); Bieschke Jan (US); Weber Petra (DE); Winklhofer Konstanze F (DE); Tatzelt Joerg (DE); Hard F Ulrich (DE); Wuensch Gerda (DE); Hoegen Tobias Johannes (DE). WO2005116640 (2005)
190. Ludwig Maximilians Uni Muenche (DE); Max Planck Gesellschaft (DE). EP1751553 (2007)
191. Bertsch U, Winklhofer KF, Hirschberger T, et al. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 2005;79(12):7785-91
192. Kawatake S, Nishimura Y, Sakaguchi S, Iwaki T, Doh-Ura K. Surface plasmon resonance analysis for the screening of antiprion compounds. Biol Pharm Bull 2006;29(5):927-32
193. Kuwata K, Nishida N, Matsumoto T, et al. Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci USA 2007;104(29):11921-6
194. Kuwata Kazuo; Nishida Noriyuki; Katamine Shigeru. JP2005120002 (2005)
195. Dohgu S, Yamauchi A, Takata F, et al. Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier. Cell Mol Neurobiol 2004;24(2):205-17
196. Univ Texas (US); Castilla Joaquin (US); SAA Paula (US); Soto Claudio (US). WO2006113915 (2006)
197. Univ Texas. US2006263767 (2006)
198. Saa P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science 2006;313(5783):92-4
199. Atarashi R, Moore RA, Sim VL, et al. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nat Methods 2007;4(8):645-50